^
    Back
    Association details:
    Biomarker:MTOR mutation
    Cancer:Renal Cell Carcinoma
    Drug:sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ESMO 2019
    Title:

    PHASE 3 TRIAL OF ADJUVANT SUNITINIB IN PATIENTS WITH HIGH-RISK RENAL CELL CARCINOMA: COMPREHENSIVE TUMOR GENOMIC AND TRANSCRIPTOMIC ANALYSES

    Published date:
    09/29/2019
    Excerpt:
    Differences in DFS were observed relative to wildtype when mutations in genes such as ARID1A, MTOR, or ROBO3 were present…
    DOI:
    10.1093/annonc/mdz249
    Trial ID:
    S-TRAC